Developing: GE HealthCare Technologies is in advanced discussions to acquire SOFIE Biosciences, a U.S. developer and manufacturer of radiopharmaceuticals, in a transaction worth roughly $1 billion, according to the Financial Times and a subsequent Reuters report. The parties have not announced a signed agreement and have declined to comment, so the price, structure and timing remain subject to change. Even so, the talks are strategically notable because GE HealthCare already works with SOFIE on investigational PET imaging agents. A purchase would therefore be less about entering an unfamiliar field than about bringing a partner, its radiopharmacy network and a developing oncology pipeline more directly inside GE HealthCare's pharmaceutical-diagnostics business.
The reported valuation is significant for a company that private-equity investor Trilantic valued at up to about $550 million in 2024, although that earlier figure is not directly comparable with a potential acquisition price and does not establish a precise takeover premium. The Financial Times said an announcement could come soon if negotiations conclude and described the deal as potentially GE HealthCare's second significant acquisition since its 2023 separation from General Electric. For shareholders, the central question is whether management can use M&A to create a more durable mix of recurring diagnostic-drug revenue around its large installed base of imaging equipment without paying too aggressively for assets whose most valuable products are still moving through clinical development.
The industrial logic starts with an existing relationship. In October 2023, GE HealthCare and SOFIE signed an exclusive global licensing agreement covering two fibroblast activation protein inhibitor, or FAPI, PET radiotracers: gallium-68 FAPI-46 and, outside the United States, fluorine-18 FAPI-74. GE HealthCare said at the time that its pharmaceutical-diagnostics agents support around 100 million imaging procedures a year globally. FAPI tracers are designed to target fibroblast activation protein, which is highly expressed in cancer-associated fibroblasts across many tumour types. That makes the platform potentially useful for imaging cancers in which conventional approaches can struggle to define the extent of disease.
Why radiopharmaceuticals fit GE HealthCare's strategy
Radiopharmaceuticals sit at an attractive intersection of medical imaging, specialised manufacturing and recurring consumables. Unlike a scanner sale, which is a large but relatively infrequent capital purchase, an imaging agent is used each time a qualifying diagnostic procedure is performed. The business also rewards scale because many radioactive tracers have short half-lives and require tightly coordinated production and distribution close to hospitals. SOFIE describes itself as having a broad U.S. radiopharmaceutical production and distribution network alongside contract-manufacturing capabilities. In Moostrade's view, combining that network with GE HealthCare's imaging hardware, installed customer relationships and global diagnostics franchise could improve control over both the technology and delivery chain, although the commercial benefit would depend on approvals, adoption and integration execution.
The oncology pipeline adds another layer. SOFIE began Phase 3 development of fluorine-18 FAPI-74 in late 2025, with separate trials in gastroesophageal cancers and pancreatic ductal adenocarcinoma. The pancreatic study dosed its first patient in February 2026 and is planned across 18 sites with an estimated 200 participants over 24 months. Those trials are evaluating whether FAPI-74 PET/CT can improve detection of metastatic disease. The programmes remain investigational, and positive earlier-stage signals do not guarantee regulatory approval or commercial success. Still, owning the developer rather than only licensing selected rights could give GE HealthCare greater strategic exposure to future FAPI diagnostics if the Phase 3 work ultimately supports broader clinical use.
For GEHC investors, the deal would arrive during a period of portfolio reshaping. The Financial Times reported that the company is reviewing its patient-care-solutions division while activist investor Trian has increased its GE HealthCare stake to nearly $200 million. That backdrop increases the importance of capital allocation. Buying SOFIE could be interpreted as a decision to concentrate more resources on higher-specialisation imaging and pharmaceutical diagnostics, where GE HealthCare can potentially connect equipment, software and tracers. The counterargument is valuation and execution risk: a roughly $1 billion transaction would need enough clinical, manufacturing and commercial upside to justify acquiring a business that was valued materially lower only two years ago.
The immediate market impact is likely to be company-specific rather than index-moving, but the transaction would be useful evidence about where healthcare capital is concentrating. Large imaging companies increasingly want exposure not only to scanners but to molecular diagnostics and theranostics, areas that can produce recurring revenue and deeper clinical integration. A completed deal could also put a higher strategic value on smaller radiopharmaceutical developers with differentiated pipelines or manufacturing networks. Conversely, if negotiations collapse over price or diligence, investors may treat that as a sign GE HealthCare is unwilling to stretch its balance sheet merely to accelerate portfolio repositioning.
The first signal is simple: whether GE HealthCare and SOFIE confirm a definitive agreement and disclose the purchase price, funding method and expected closing timetable. Investors should then focus on any revenue or margin contribution management attributes to SOFIE, the treatment of the existing FAPI licensing arrangement, and whether GE HealthCare gives new guidance on the strategic review of patient care solutions. Beyond the transaction itself, the two Phase 3 FAPI-74 studies are the key clinical milestones. Progress on enrolment, regulatory discussions and eventual diagnostic-performance data will matter more to the long-run value of the oncology platform than the headline takeover price alone.
